Literature DB >> 6781910

Genetic control of sensitivity to Moloney leukemia virus in mice. III. The three H-2 linked Rmv genes are immune response genes controlling the antiviral antibody response.

P Debré, B Boyer, S Gisselbrecht, A Bismuth, J P Lévy.   

Abstract

It has been shown previously that three different H-2-associated genes control the resistance to viremia and leukemia in Moloney virus-infected mice: Rmv. 1, mapping to the I-A or less probably K regions; Rmv. 2, mapping to the I-C, S or G regions and Rmv. 3, mapping to the D or T regions. Experiments have been performed to determine the role of these genes in the control of the antibody responses directed against Moloney murine leukemia virus (M. MuLV) virions and/or leukemic cells. The inoculation of infectious M.MuLV failed to provide conclusive responses due to unequal replication of the virus in different inbred strains resulting in variable antigenic stimulations and/or in vivo antibody absorptions. The use of inactivated M.MuLV as antigen allowed to avoid these problems. It showed that (2) the IgG-specific antiM.MuLV response is controlled by H-2 linked genes, (b) a clear correlation exists between high or low-responder phenotypes and the resistance or susceptibility to M.MuLV infection and (c) all three Rmv genes behave like immune response genes. These results were not surprising for Rmv. 1 and Rmv. 2 which map in the I region of the major histocompatibility complex. It was more puzzling for Rmv. 3. Further experiments are necessary to determine the exact mechanism by which this gene controls the immune response.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6781910     DOI: 10.1002/eji.1830101205

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

1.  Anti HTLV-I antibodies and HLA phenotypes in the West Indies.

Authors:  M Chavance; N Monplaisir; I Valette; L Schaffar-Deshayes; C Raffoux
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

Review 2.  Role of the major histocompatibility complex in resistance to viral leukemia; its effect on the preleukemic stage of leukemogenesis.

Authors:  P Lonai; E Katz; N Haran-Ghera
Journal:  Springer Semin Immunopathol       Date:  1982

3.  Major histocompatibility complex class II-regulated immunity to murine leukemia virus protects against early T- but not late B-cell lymphomas.

Authors:  W L Vasmel; M Zijlstra; T Radaszkiewicz; C J Leupers; R E de Goede; C J Melief
Journal:  J Virol       Date:  1988-09       Impact factor: 5.103

4.  Oncogenic activity of the BK type of human papova virus in inbred rat strains.

Authors:  G Noss; G Stauch
Journal:  Arch Virol       Date:  1984       Impact factor: 2.574

5.  A linkage study between HLA and cutaneous malignant melanoma or precursor lesions or both.

Authors:  F Demenais; J P Cesarini; M Daveau; B Cavelier; J Gony; N Feingold; J Hors
Journal:  J Med Genet       Date:  1984-12       Impact factor: 6.318

6.  HLA and adult T cell leukaemia: HLA-linked genes controlling susceptibility to human T cell leukaemia virus type I.

Authors:  H Uno; K Kawano; H Matsuoka; K Tsuda
Journal:  Clin Exp Immunol       Date:  1988-02       Impact factor: 4.330

7.  Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations.

Authors:  W M Kast; A M Bronkhorst; L P de Waal; C J Melief
Journal:  J Exp Med       Date:  1986-09-01       Impact factor: 14.307

8.  Imbalanced MHC class II molecule expression at surface of murine B cell lymphomas.

Authors:  M Zijlstra; W L Vasmel; M Voormanns; R E de Goede; H J Schoenmakers; J Nieland; R M Slater; C J Melief
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

9.  Maneuvering for advantage: the genetics of mouse susceptibility to virus infection.

Authors:  Seung-Hwan Lee; Ken Dimock; Douglas A Gray; Nicole Beauchemin; Kathryn V Holmes; Majid Belouchi; John Realson; Silvia M Vidal
Journal:  Trends Genet       Date:  2003-08       Impact factor: 11.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.